[{"id":"0275af4d-adea-470c-80d3-2b61aa1c8803","acronym":"","url":"https://clinicaltrials.gov/study/NCT01950390","created_at":"2021-01-18T08:50:38.167Z","updated_at":"2025-02-25T12:26:04.772Z","phase":"Phase 2","brief_title":"Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT01950390","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Yervoy (ipilimumab) • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • CS1002 (ipilimumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 169","initiation":"Initiation: 01/24/2014","start_date":" 01/24/2014","primary_txt":" Primary completion: 10/06/2021","primary_completion_date":" 10/06/2021","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2025-02-24"},{"id":"6a7737ea-7363-4409-b641-c11409e515ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT04181060","created_at":"2021-01-18T20:23:16.793Z","updated_at":"2025-02-25T12:37:29.255Z","phase":"Phase 3","brief_title":"Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer","source_id_and_acronym":"NCT04181060","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tagrisso (osimertinib) • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 12/28/2020","start_date":" 12/28/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-24"},{"id":"c79faf97-f729-4398-957b-5d83e409d779","acronym":"COMMIT","url":"https://clinicaltrials.gov/study/NCT02997228","created_at":"2021-01-18T14:45:08.921Z","updated_at":"2025-02-25T12:26:35.429Z","phase":"Phase 3","brief_title":"Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study","source_id_and_acronym":"NCT02997228 - COMMIT","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • MSI-H/dMMR","tags":["PD-L1 • MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • 5-fluorouracil • oxaliplatin • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • fluorouracil topical • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 01/19/2018","start_date":" 01/19/2018","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-24"},{"id":"f40744c7-793a-45a6-9a12-58302eebd647","acronym":"ECOG-ACRIN 5103","url":"https://clinicaltrials.gov/study/NCT00433511","created_at":"2021-01-18T01:31:45.738Z","updated_at":"2025-02-25T13:47:58.144Z","phase":"Phase 3","brief_title":"Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer","source_id_and_acronym":"NCT00433511 - ECOG-ACRIN 5103","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER","pipe":"","alterations":" ","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 4994","initiation":"Initiation: 11/02/2007","start_date":" 11/02/2007","primary_txt":" Primary completion: 01/07/2014","primary_completion_date":" 01/07/2014","study_txt":" Completion: 02/22/2025","study_completion_date":" 02/22/2025","last_update_posted":"2025-02-20"},{"id":"8e80751c-1262-45dc-bec5-fce7b2699448","acronym":"","url":"https://clinicaltrials.gov/study/NCT00217737","created_at":"2021-01-18T00:44:25.249Z","updated_at":"2025-02-25T14:39:13.469Z","phase":"Phase 3","brief_title":"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer","source_id_and_acronym":"NCT00217737","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • MSH2","pipe":"","alterations":" ","tags":["MSI • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • fluorouracil topical • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3610","initiation":"Initiation: 09/06/2005","start_date":" 09/06/2005","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2025-02-14"},{"id":"424f1715-a08a-4e86-a255-1bc30e3c69e6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03203525","created_at":"2021-01-18T15:47:47.088Z","updated_at":"2025-02-25T15:42:56.837Z","phase":"Phase 1","brief_title":"Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer","source_id_and_acronym":"NCT03203525","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PIK3CA • PTEN","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • temsirolimus • pegylated liposomal doxorubicin • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • fluorouracil topical • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • doxorubicin liposomal"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 06/23/2020","start_date":" 06/23/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-10"},{"id":"1d7c6809-da8f-46e6-b1c7-b65f0af673cc","acronym":"CALGB 40603","url":"https://clinicaltrials.gov/study/NCT00861705","created_at":"2021-01-18T03:17:10.131Z","updated_at":"2025-02-25T16:36:01.005Z","phase":"Phase 2","brief_title":"Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery","source_id_and_acronym":"NCT00861705 - CALGB 40603","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 454","initiation":"Initiation: 05/15/2009","start_date":" 05/15/2009","primary_txt":" Primary completion: 08/01/2014","primary_completion_date":" 08/01/2014","study_txt":" Completion: 02/22/2025","study_completion_date":" 02/22/2025","last_update_posted":"2025-02-06"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"972ad6b2-046a-4952-a809-07b8eb832df8","acronym":"CALGB-40503","url":"https://clinicaltrials.gov/study/NCT00601900","created_at":"2021-01-18T02:13:51.918Z","updated_at":"2025-02-25T16:35:58.371Z","phase":"Phase 3","brief_title":"Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer","source_id_and_acronym":"NCT00601900 - CALGB-40503","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER expression","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • letrozole • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Soltamox (tamoxifen citrate) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 394","initiation":"Initiation: 09/24/2008","start_date":" 09/24/2008","primary_txt":" Primary completion: 06/30/2014","primary_completion_date":" 06/30/2014","study_txt":" Completion: 05/30/2025","study_completion_date":" 05/30/2025","last_update_posted":"2025-02-06"},{"id":"e118d91b-52cd-4056-bb0a-550364e29b58","acronym":"","url":"https://clinicaltrials.gov/study/NCT03511963","created_at":"2021-01-18T17:17:09.843Z","updated_at":"2025-02-25T13:48:31.885Z","phase":"Phase 3","brief_title":"A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC","source_id_and_acronym":"NCT03511963","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • Hanbeitai (bevacizumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 677","initiation":"Initiation: 04/09/2018","start_date":" 04/09/2018","primary_txt":" Primary completion: 04/15/2020","primary_completion_date":" 04/15/2020","study_txt":" Completion: 04/20/2023","study_completion_date":" 04/20/2023","last_update_posted":"2024-12-31"},{"id":"17e8ba18-b2fc-4fc4-a9e2-96bb597a8a60","acronym":"ASTRUM-015","url":"https://clinicaltrials.gov/study/NCT04547166","created_at":"2021-01-18T21:45:04.951Z","updated_at":"2025-02-25T13:48:56.719Z","phase":"Phase 2/3","brief_title":"A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)","source_id_and_acronym":"NCT04547166 - ASTRUM-015","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • capecitabine • oxaliplatin • Hetronifly (serplulimab) • Hanbeitai (bevacizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 568","initiation":"Initiation: 03/10/2021","start_date":" 03/10/2021","primary_txt":" Primary completion: 09/24/2025","primary_completion_date":" 09/24/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2024-10-17"},{"id":"8c77c515-8fd7-47a1-b2a0-d210db442390","acronym":"","url":"https://clinicaltrials.gov/study/NCT00977574","created_at":"2021-01-18T03:48:50.533Z","updated_at":"2024-07-02T16:35:03.140Z","phase":"Phase 2","brief_title":"Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer","source_id_and_acronym":"NCT00977574","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AKT1","pipe":"","alterations":" ","tags":["AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • paclitaxel • temsirolimus • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Ixempra (ixabepilone) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • patupilone (EPO 906)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 349","initiation":"Initiation: 09/14/2009","start_date":" 09/14/2009","primary_txt":" Primary completion: 01/31/2015","primary_completion_date":" 01/31/2015","study_txt":" Completion: 03/06/2025","study_completion_date":" 03/06/2025","last_update_posted":"2024-05-17"},{"id":"c6296d46-2509-4857-a66a-8bdd1dea5322","acronym":"BEAT-MBM","url":"https://clinicaltrials.gov/study/NCT03175432","created_at":"2021-01-18T15:39:32.617Z","updated_at":"2024-07-02T16:35:02.815Z","phase":"Phase 2","brief_title":"Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases","source_id_and_acronym":"NCT03175432 - BEAT-MBM","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • BRAF • PD-1","pipe":" | ","alterations":" PD-L1 expression • BRAF V600 • BRAF wild-type","tags":["PD-L1 • BRAF • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • Cotellic (cobimetinib) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 06/15/2017","start_date":" 06/15/2017","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-05-17"},{"id":"e9f712c9-43ca-4d3b-9a6c-4c80e514d787","acronym":"NCI-2018-01503","url":"https://clinicaltrials.gov/study/NCT03587311","created_at":"2021-01-29T07:17:35.675Z","updated_at":"2024-07-02T16:35:02.670Z","phase":"Phase 2","brief_title":"Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT03587311 - NCI-2018-01503","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • anetumab ravtansine (BAY 94-9343) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 10/12/2018","start_date":" 10/12/2018","primary_txt":" Primary completion: 10/21/2024","primary_completion_date":" 10/21/2024","study_txt":" Completion: 10/21/2024","study_completion_date":" 10/21/2024","last_update_posted":"2024-05-17"},{"id":"cd2f0c6b-9287-4ecc-b80c-c18fadf4071e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03074513","created_at":"2021-01-19T13:46:53.660Z","updated_at":"2024-07-02T16:35:03.337Z","phase":"Phase 2","brief_title":"Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors","source_id_and_acronym":"NCT03074513","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 133","initiation":"Initiation: 03/03/2017","start_date":" 03/03/2017","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-05-16"},{"id":"ec03da03-d224-4590-ad5d-e4c428f4a16c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04227028","created_at":"2021-01-18T20:33:34.334Z","updated_at":"2024-07-02T16:35:05.549Z","phase":"Phase 1","brief_title":"Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC","source_id_and_acronym":"NCT04227028","lead_sponsor":"City of Hope Medical Center","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Alunbrig (brigatinib) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 03/09/2020","start_date":" 03/09/2020","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2024-05-07"},{"id":"69622ca4-3967-4dd1-94fb-bb4cbf2391b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03181100","created_at":"2021-01-17T18:00:20.904Z","updated_at":"2024-07-02T16:35:06.482Z","phase":"Phase 2","brief_title":"Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer","source_id_and_acronym":"NCT03181100","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Cotellic (cobimetinib) • albumin-bound paclitaxel • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/27/2017","start_date":" 07/27/2017","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2024-05-02"},{"id":"653b0929-1d57-4b2a-adf0-7e0b59367122","acronym":"","url":"https://clinicaltrials.gov/study/NCT02142803","created_at":"2021-01-18T09:57:08.346Z","updated_at":"2024-07-02T16:35:16.708Z","phase":"Phase 1","brief_title":"TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors","source_id_and_acronym":"NCT02142803","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • sapanisertib (CB-228) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/20/2014","start_date":" 05/20/2014","primary_txt":" Primary completion: 12/31/2020","primary_completion_date":" 12/31/2020","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-03-01"},{"id":"8e2f554f-5b71-4b80-85eb-7d4289eed34a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02456857","created_at":"2021-01-18T11:47:13.758Z","updated_at":"2024-07-02T16:35:19.566Z","phase":"Phase 2","brief_title":"Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative","source_id_and_acronym":"NCT02456857","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER • PGR • VIM","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR • VIM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • everolimus • pegylated liposomal doxorubicin • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 01/12/2016","start_date":" 01/12/2016","primary_txt":" Primary completion: 05/24/2023","primary_completion_date":" 05/24/2023","study_txt":" Completion: 05/24/2023","study_completion_date":" 05/24/2023","last_update_posted":"2024-02-13"},{"id":"0b6d7e60-5588-4d27-b84f-436660d0c1bd","acronym":"NRG-GY009","url":"https://clinicaltrials.gov/study/NCT02839707","created_at":"2021-01-18T13:56:21.115Z","updated_at":"2024-07-02T16:35:29.911Z","phase":"Phase 2/3","brief_title":"Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT02839707 - NRG-GY009","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • pegylated liposomal doxorubicin • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 443","initiation":"Initiation: 06/23/2017","start_date":" 06/23/2017","primary_txt":" Primary completion: 05/09/2023","primary_completion_date":" 05/09/2023","study_txt":" Completion: 09/21/2024","study_completion_date":" 09/21/2024","last_update_posted":"2023-11-08"},{"id":"72fc68c9-215a-40a6-91f6-d9f55c3287fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02020707","created_at":"2021-01-18T09:14:56.657Z","updated_at":"2024-07-02T16:35:35.067Z","phase":"Phase 1","brief_title":"Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers","source_id_and_acronym":"NCT02020707","lead_sponsor":"Mayo Clinic","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • albumin-bound paclitaxel • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 73","initiation":"Initiation: 02/24/2014","start_date":" 02/24/2014","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-10-02"},{"id":"97633adb-6d2e-4686-b967-d9468938de97","acronym":"HLX10-002-NSCLC301","url":"https://clinicaltrials.gov/study/NCT03952403","created_at":"2021-01-18T19:27:10.739Z","updated_at":"2025-02-25T13:48:42.589Z","phase":"Phase 3","brief_title":"A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT03952403 - HLX10-002-NSCLC301","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" PD-L1 • ALK • TMB • MSI • ROS1","pipe":" | ","alterations":" PD-L1 expression • ALK mutation","tags":["PD-L1 • ALK • TMB • MSI • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Hetronifly (serplulimab) • Hanbeitai (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 643","initiation":"Initiation: 12/02/2019","start_date":" 12/02/2019","primary_txt":" Primary completion: 10/01/2023","primary_completion_date":" 10/01/2023","study_txt":" Completion: 03/15/2024","study_completion_date":" 03/15/2024","last_update_posted":"2023-08-08"},{"id":"520c8dda-afa2-4366-9d2a-562de3330878","acronym":"","url":"https://clinicaltrials.gov/study/NCT02921269","created_at":"2021-01-18T14:20:33.065Z","updated_at":"2024-07-02T16:35:55.074Z","phase":"Phase 2","brief_title":"Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer","source_id_and_acronym":"NCT02921269","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 03/10/2017","start_date":" 03/10/2017","primary_txt":" Primary completion: 10/01/2020","primary_completion_date":" 10/01/2020","study_txt":" Completion: 01/13/2021","study_completion_date":" 01/13/2021","last_update_posted":"2023-02-21"},{"id":"73ded696-b188-40bd-9d00-ba4f1710bd92","acronym":"CALGB 40502","url":"https://clinicaltrials.gov/study/NCT00785291","created_at":"2021-01-18T02:58:05.514Z","updated_at":"2024-07-02T16:36:02.771Z","phase":"Phase 3","brief_title":"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer","source_id_and_acronym":"NCT00785291 - CALGB 40502","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PGR","pipe":" | ","alterations":" HER-2 overexpression • HER-2 negative","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • albumin-bound paclitaxel • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Ixempra (ixabepilone) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • patupilone (EPO 906)"],"overall_status":"Completed","enrollment":" Enrollment 799","initiation":"Initiation: 10/13/2008","start_date":" 10/13/2008","primary_txt":" Primary completion: 12/31/2013","primary_completion_date":" 12/31/2013","study_txt":" Completion: 06/15/2017","study_completion_date":" 06/15/2017","last_update_posted":"2022-10-10"}]